Skip to content

Ketamine: all studies

Page 23 of 448: studies 221 to 230 of 4,475, newest first. Back to the ketamine overview

Research

Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.

Psychopharmacology July 1, 2026 Sarah Ann Smith, Haseeb Mohammad, Lik Hang N Lee et al.

Interest in psychedelic drugs has increased rapidly because of their potential therapeutic role in psychiatric disorders. Impairments in the sociocognitive skills needed to build and maintain social relationships are prominent features of many psychiatric and neurodevelopmental disorders. Emerging evidence suggests that compounds such as 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid...

DOI: 10.1007/s00213-026-07110-y (opens in new tab) Full text (opens in new tab) Psychedelic drugs Scoping review Social cognition

Linagliptin, a Selective DPP-4 Inhibitor, Attenuates Ketamine- and Diazepam-Induced Deficits in Passive Avoidance Performance in Mice

Brain Science June 30, 2026 Krzysztof Fronc, Piotr Listos, Paulina Kasprzak et al.

Highlights Linagliptin attenuated ketamine-induced passive avoidance deficits in mice. Linagliptin increased BDNF levels in the prefrontal cortex but not in the hippocampus. Abstract Background: Linagliptin, a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor approved for the treatment of type 2 diabetes, enhances glucagon-like peptide-1 (GLP-1) signaling. Because GLP-1...

A review of the therapeutic and neuroprotective properties of ketamine

Medical Science of Ukraine June 30, 2026 Viacheslav Zaika, Yan Tytarenko

Relevance. Depression is one of the leading causes of disability worldwide, and a significant proportion of patients suffer from treatment-resistant forms of the disorder. An innovative approach involves the use of ketamine and esketamine, which are capable of inducing a “window of neuroplasticity” – a period of enhanced synaptogenesis and the formation of new neural connections. Theoretically,...

Psychotherapy and Ketamine: How Does This Combination Affect the Duration of the Antidepressant Effect?

Psychosomatic Medicine and General Practice June 30, 2026 Viacheslav Zaika, Yan Tytarenko

Background. Ketamine provides rapid but short-lived antidepressant effects for treatment-resistant depression (TRD). To prolong this response, ketamine-assisted therapy (KAT) combines the drug's pharmacological effects with psychotherapy. Aim. This study aims to analyze scientific evidence regarding the synergistic interaction between ketamine's pharmacological effects and modern...

Ketamine renaissance: Expanding horizons from anesthesia to depression and pain

Asian Journal of Medical Sciences June 30, 2026 Raja Suhail Shounthoo, Ajaiz Rasool, Athar Un Nisa Quraishi et al.

Ketamine, a dissociative anesthetic introduced in the 1960s, has re-emerged as a versatile therapeutic agent extending beyond its traditional perioperative role. Its rapid antidepressant action in treatment-resistant depression and efficacy in acute and chronic pain syndromes have driven what is termed the “ketamine renaissance.” Unlike conventional monoaminergic antidepressants, ketamine...

Comprehensive Systematic Review of Esketamine Nasal Spray as a Standalone Rapid-Acting Treatment for Treatment-Resistant Depression: Integrating Clinical Trial Data and Emerging Real-World Evidence on Efficacy, Safety, And Relapse Prevention

International Journal of Drug Delivery Technology June 30, 2026 Angelin Grace Thomas, Dhivyaprasath Palaniappan, Sagar Guruswamy et al.

Major depressive disorder, or MDD, is a common cause of disability around the world. Treatment-resistant depression, or TRD, is a tough challenge. Many people do not respond well to treatment, which increases the risk of relapse and suicide. Esketamine is a new treatment that comes as a nasal spray. It works quickly and targets a specific brain receptor. This review looks at research from...

Ketamine-Augmented Hypnotherapy

Preprints.org June 30, 2026 Dirk Revenstorf, Joost (j.b.c.) Mertens, Martin Schipplick preprint

The therapeutic use of ketamine and other psychoactive substances in psychiatry is attracting growing research interest, particularly in treatment-resistant depression and related conditions refractory to conventional care. Ketamine exerts direct pharmacological antidepressant effects through NMDA receptor antagonism and downstream neuroplastic mechanisms; its combination with structured...

Exposure to Ketamine and 2-Fluorodeschloroketamine Impairs Mitochondrial Oxidative Phosphorylation in Human Cerebral Organoids: Implications for Neurodevelopmental Toxicity.

Current Neuropharmacology June 30, 2026 Jiaying Wang, Rui Zhang, Yuanyuan Ma et al.

Ketamine and its structural analog, 2-Fluorodeschloroketamine, both potent stimulants, can induce euphoria but also cause neurotoxicity, cognitive decline, and neurodevelopmental deficits in the fetus. However, the molecular mechanisms responsible for these neurodevelopmental abnormalities are not yet fully elucidated, particularly concerning effects that are specific to certain cell types....

DOI: 10.2174/011570159x445463260422181312 (opens in new tab) Full text (opens in new tab) 2-fluorodeschloroketamine Human cerebral organoid Mitochondrial dysfunction Neurodevelopment +1

Readability of informed consent forms from ClinicalTrials.gov in ketamine clinical trials for mental health conditions: a cross-sectional analysis.

Therapeutic Advances in Psychopharmacology June 29, 2026 Damian Swieczkowski, Aleksander Kwaśny, Wiesław Jerzy Cubała

Background: Ensuring participants understand informed consent forms (ICFs) is a core ethical requirement of clinical research, particularly in psychiatry, where cognitive and affective symptoms can compromise decisional capacity. As ketamine-based interventions are increasingly studied for mental health conditions, the readability of consent materials in these trials warrants systematic...

DOI: 10.1177/20451253261456385 (opens in new tab) Psychiatric disorders Health literacy Informed consent forms Readability assessment +1

The Dark Side of Ketamine: Brain, Bladder, and Beyond: a Focused Clinical Review for Emergency Medicine Clinicians

Anatolian Journal of Emergency Medicine June 28, 2026 Sergey Motov

Ketamine is an indispensable therapeutic in emergency medicine, yet its pharmacologic profile carries a unique constellation of adverse effects that emergency medicine clinicians must recognize and manage. This focused clinical review examines four categories of these ketamine-specific adverse effects encountered in the emergency department (ED): acute psycho-perceptual adverse effects (PPAEs)...

DOI: 10.54996/anatolianjem.1923782 (opens in new tab) Ketamine Adverse effect Emergency department Dissociative +6